{
    "clinical_study": {
        "@rank": "100720", 
        "arm_group": [
            {
                "arm_group_label": "Treatment I", 
                "arm_group_type": "Experimental", 
                "description": "1 DLBS3233 capsule 100 mg (once daily) and 1 placebo caplet of Metformin XR (twice daily)"
            }, 
            {
                "arm_group_label": "Treatment II", 
                "arm_group_type": "Active Comparator", 
                "description": "1 Metformin XR caplet 750 mg (twice daily) and 1 placebo capsule of DLBS3233 (once daily)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a 2-arm, randomized, double-blind, double-dummy, and controlled clinical study, with\n      6 months of treatment to evaluate the clinical and metabolic efficacy of DLBS3233 in\n      improving reproductive parameters and to evaluate the safety of DLBS3233 in women with\n      polycystic ovary syndrome compared with metformin, as an active control."
        }, 
        "brief_title": "Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Polycystic Ovary Syndrome (PCOS)", 
        "condition_browse": {
            "mesh_term": "Polycystic Ovary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "There will be 2 groups of treatment; each group will consist of 62 subjects with the\n      treatment regimens :\n\n        -  Treatment I : 1 capsule of DLBS3233 100 mg (once daily) and 1 placebo caplet of\n           Metformin XR (twice daily)\n\n        -  Treatment II : 1 caplet of Metformin XR 750 mg (twice daily) and 1 placebo capsule of\n           DLBS3233 (once daily) for 6 months of treatment.\n\n      Clinical examination to evaluate the efficacy of the investigational drug will be performed\n      at baseline and every interval of 1 month.\n\n      Laboratory examinations to evaluate the metabolic efficacy parameters and ultrasonography\n      (USG) examination will be performed at baseline, Month 3rd, and end of study (Month 6th). In\n      addition to that, USG will also be performed about 2 weeks after Month 3rd (Month 3.5th) and\n      after Month 5th (Month 5.5th).\n\n      Laboratory examinations to evaluate the reproductive efficacy parameters (reproductive\n      hormone levels) and safety, at baseline and Month 6th (end of study).\n\n      General counseling on lifestyle modification will be provided to the subjects by the\n      assigned Nutritionist. All study subjects should follow a lifestyle modification. Evaluation\n      on subjects' performance on lifestyle modification will be conducted every follow-up visit\n      by Investigator, but particularly at baseline, Month 3rd, and end of study (Month 6th) by\n      the Nutritionist."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female subjects in reproductive age (i.e. 18-40 years)\n\n          -  Subject with a diagnosis of polycystic ovary syndrome confirmed by two of the\n             Rotterdam Criteria\n\n          -  Subject with insulin resistance defined by: HOMA-IR of > 2.00\n\n        Exclusion Criteria:\n\n          -  Pregnant and lactating women\n\n          -  Subjects known to have Cushing's syndrome, late onset of congenital adrenal\n             hyperplasia, androgen-secreting tumors, uncontrolled thyroid disease,\n             hyperprolactinemia\n\n          -  Known to have current medical condition, which, is judged by the Investigator could\n             jeopardize subject's health or interfere with the study evaluation, such as diabetes\n             mellitus, uncontrolled hypertension, other cardiovascular diseases, acute or chronic\n             infections, and any known malignancies\n\n          -  Impaired renal function (serum creatinine level > 1.5 ULN)\n\n          -  Impaired liver function (serum ALT level \u2265 2.5 ULN)\n\n          -  Medically-assisted weight loss with medications or surgical procedures\n\n          -  Currently having laparoscopic ovarian diathermy (LOD)\n\n          -  Currently under treatment with in vitro fertilization (IVF) techniques\n\n          -  Have been regularly taking any medications which affect insulin sensitivity as well\n             as reproductive function (i.e. ovulation, menstrual cycle), within \u2264 3 months prior\n             to screening\n\n          -  Participating in other clinical trial within 30 days prior to screening"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "124", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01733459", 
            "org_study_id": "DLBS3233-0811"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment I", 
                "description": "1 DLBS3233 capsule 100 mg once daily for 6 months", 
                "intervention_name": "DLBS3233", 
                "intervention_type": "Drug", 
                "other_name": "Inlacin"
            }, 
            {
                "arm_group_label": "Treatment II", 
                "description": "1 Metformin XR caplet 750 mg twice daily for 6 months", 
                "intervention_name": "Metformin XR", 
                "intervention_type": "Drug", 
                "other_name": "Glumin XR"
            }, 
            {
                "arm_group_label": "Treatment I", 
                "description": "1 placebo caplet of Metformin XR twice daily for 6 months", 
                "intervention_name": "Placebo caplet of Metformin XR", 
                "intervention_type": "Drug", 
                "other_name": "Placebo caplet of Glumin XR"
            }, 
            {
                "arm_group_label": "Treatment II", 
                "description": "1 placebo capsule of DLBS3233 once daily for 6 months", 
                "intervention_name": "Placebo capsule of DLBS3233", 
                "intervention_type": "Drug", 
                "other_name": "Placebo capsule of Inlacin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Hypoglycemic Agents", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "PCOS, DLBS3233, metformin,oral anti-hyperglycemic agent", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "contact": {
                    "email": "wiryawan_permadi@yahoo.com", 
                    "last_name": "Wiryawan Permadi, Dr. dr., SpOG(K)", 
                    "phone": "+62811 2090 06"
                }, 
                "contact_backup": {
                    "email": "djuwantono@yahoo.com", 
                    "last_name": "Tono Djuwantono, Dr. dr., SpOG(K),, M.Kes", 
                    "phone": "+62811 2250 60"
                }, 
                "facility": {
                    "address": {
                        "city": "Bandung", 
                        "country": "Indonesia", 
                        "state": "West Java", 
                        "zip": "40161"
                    }, 
                    "name": "Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Wiryawan Permadi, Dr. dr., SpOG(K)", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Tono Djuwantono, Dr. dr., SpOG(K), M.Kes", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Mulyanusa A. Ritonga, Dr., SpOG", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hestiantoro@gmail.com", 
                    "last_name": "Andon Hestiantoro, dr., SpOG(K)", 
                    "phone": "+62815 1052 6366"
                }, 
                "contact_backup": {
                    "email": "kanadisuma@yahoo.com", 
                    "last_name": "Kanadi Sumapraja, dr., SpOG(K), MSc", 
                    "phone": "+62816 1821 604"
                }, 
                "facility": {
                    "address": {
                        "city": "Jakarta", 
                        "country": "Indonesia", 
                        "zip": "10430"
                    }, 
                    "name": "Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Andon Hestiantoro, dr., SpOG(K)", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Budi Wiweko, dr., SpOG(K)", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Kanadi Sumapraja, dr., SpOG(K), MSc", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "R. Muharam, dr., SpOG(K)", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Cynthia Agnes Susanto, dr., B. Med. Sc", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of DLBS3233 in the Management of Polycystic Ovary Syndrome (PCOS)", 
        "overall_contact": {
            "email": "hestiantoro@gmail.com", 
            "last_name": "Andon Hestiantoro, dr., SpOG(K)", 
            "phone": "+62815 1052 6366"
        }, 
        "overall_contact_backup": {
            "email": "wiryawan_permadi@yahoo.com", 
            "last_name": "Wiryawan Permadi, Dr. dr., SpOG(K)", 
            "phone": "+62811 2090 06"
        }, 
        "overall_official": [
            {
                "affiliation": "Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Indonesia, dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia", 
                "last_name": "Andon Hestiantoro, dr., SpOG(K)", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Department of Obstetrics and Gynecology, Faculty of Medicine, University of Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia", 
                "last_name": "Wiryawan Permadi, Dr. dr., SpOG(K)", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "HOMA-IR reduction from baseline to Month 6th (end of study)", 
            "measure": "HOMA-IR reduction", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01733459"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate: number of subjects having normalization of menses within 6 months of treatment", 
                "measure": "Response rate: number of subjects having normalization of menses", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Response rate: pregnancy within 6 months of treatment", 
                "measure": "Response rate: pregnancy", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Reduction of BMI from baseline to every follow-up time-point evaluation", 
                "measure": "Reduction of BMI", 
                "safety_issue": "No", 
                "time_frame": "1, 2, 3, 4, 5, and 6 Months"
            }, 
            {
                "description": "Change of body fat composition from baseline to every follow-up time-point evaluation", 
                "measure": "Change of body fat composition", 
                "safety_issue": "No", 
                "time_frame": "1, 2, 3, 4, 5, and 6 months"
            }, 
            {
                "description": "Change of waist circumference from baseline to every follow-up time-point evaluation", 
                "measure": "Change of waist circumference", 
                "safety_issue": "No", 
                "time_frame": "1, 2, 3, 4, 5, and 6 months"
            }, 
            {
                "description": "Reduction (indicating improvement) of S/A ratio (i.e. ratio of mean stromal echogenicity to mean echogenicity of entire ovary) from baseline to Month 3rd and Month 6th (end of study)", 
                "measure": "Reduction of S/A ratio", 
                "safety_issue": "No", 
                "time_frame": "3 and 6 months"
            }, 
            {
                "description": "Reduction of free testosterone level (calculated) from baseline to Month 6th (end of study)", 
                "measure": "Reduction of free testosterone level (calculated)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change of luteinizing hormone (LH) level from baseline to Month 6th (end of study)", 
                "measure": "Change of luteinizing hormone (LH) level", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio from baseline to Month 6th (end of study)", 
                "measure": "Change of luteinizing hormone (LH) / follicle stimulating hormone (FSH) ratio", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Change of Ferriman-Gallwey Score from baseline to Month 3rd and Month 6th (end of study)", 
                "measure": "Change of Ferriman-Gallwey Score", 
                "safety_issue": "No", 
                "time_frame": "3 and 6 months"
            }, 
            {
                "description": "Improvement of glucose tolerance (reduction of FPG and 2-hour PPPG) from baseline to Month 3rd and Month 6th (end of study)", 
                "measure": "Improvement of glucose tolerance", 
                "safety_issue": "No", 
                "time_frame": "3 and 6 months"
            }, 
            {
                "description": "Fasting insulin level reduction from baseline to Month 3rd and Month 6th (end of study)", 
                "measure": "Fasting insulin level reduction", 
                "safety_issue": "No", 
                "time_frame": "3 and 6 months"
            }, 
            {
                "description": "HOMA-IR reduction from baseline to Month 3rd", 
                "measure": "HOMA-IR reduction", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Lipid profile improvement (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides level) from baseline to Month 3rd and Month 6th (end of study)", 
                "measure": "Lipid profile improvement", 
                "safety_issue": "No", 
                "time_frame": "3 and 6 months"
            }, 
            {
                "description": "Vital signs (blood pressure, pulse rate, respiration rate) from baseline to every follow-up time-point evaluation", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "1, 2, 3, 4, 5, and 6 months"
            }, 
            {
                "description": "Electrocardiography (ECG) from baseline to Month 6th (end of study)", 
                "measure": "Electrocardiography (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Liver function (serum AST, ALT, alkaline phosphatase, \u03b3-glutamyl transferase) from baseline to Month 6th (end of study)", 
                "measure": "Liver function", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Renal function (serum creatinine, BUN) from baseline to Month 6th (end of study)", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Adverse events as well as number of events and subjects experiencing the events will be observed and evaluated throughout study period (6 months) and until all adverse events have been recovered or stabilized", 
                "measure": "Number of adverse events and subjects with events", 
                "safety_issue": "Yes", 
                "time_frame": "During 6 months"
            }, 
            {
                "description": "Presence of ovulation will be observed using trans-vaginal USG at Month 3.5th and Month 5.5th.\nOn Day 12th of the menstrual cycle, the USG will be performed on the subject. If there is no dominant follicle found on Day 12th, a serial USG examination will be performed at the interval of 3 days, up to Day 18th. On USG, when there is dominant follicle found, the presence of ovulation will be confirmed by measuring the progesterone level in the next 7 days. If until Day 18th there is no dominant follicle found, the ovulation is counted as absent.", 
                "measure": "Ovulation rate", 
                "safety_issue": "No", 
                "time_frame": "3.5 months and 5.5 months"
            }, 
            {
                "description": "Change of Anti Mullerian Hormone (AMH) level from baseline to the end of study\nThis additional secondary endpoint is site-specific (applicable only for site 01, i.e. Dr. Cipto Mangunkusumo Hospital, Jakarta).", 
                "measure": "Change of Anti Mullerian Hormone (AMH) level", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }
        ], 
        "source": "Dexa Medica Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexa Medica Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}